Lücker P W, Tinhof W, Wetzelsberger N, Weyers W, Brodbeck R
Arzneimittelforschung. 1983;33(3):453-8.
Pharmacokinetics and absolute bioavailability of 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide (bromopride, Viaben), in various preparations (bromopride injection solution, bromopride suppositories for adults, drops and capsules, respectively) in various dosages were calculated. Several investigations were performed: Study I: Absolute bioavailability of bromopride suppositories for adults (cross-over). Study 2: Pharmacokinetics of Bromopride drops after single dose of 15 and 30 mg bromopride as well as after multiple dose of 15 mg bromopride (Confarma). Study 3: Pharmacokinetics of bromopride capsules (Confarma). The chemical analysis was made for all studies with a nearly identical HPLC-method so that the results of the various studies were comparable. The studies led to the following result: The bioavailability of the substance bromopride amounts to about 70% and increases after multiple administration to about 90%. Statistically there is no difference between the bioavailabilities of the individual formulations.
计算了4-氨基-5-溴-N-[2-(二乙氨基)乙基]-2-甲氧基苯甲酰胺（溴必利，胃复安）在各种剂型（溴必利注射液、成人用溴必利栓剂、滴剂和胶囊）、不同剂量下的药代动力学和绝对生物利用度。进行了多项研究：研究I：成人用溴必利栓剂的绝对生物利用度（交叉试验）。研究2：单次服用15毫克和30毫克溴必利以及多次服用15毫克溴必利后溴必利滴剂的药代动力学（Confarma公司）。研究3：溴必利胶囊的药代动力学（Confarma公司）。所有研究均采用几乎相同的高效液相色谱法进行化学分析，以便各项研究结果具有可比性。研究得出以下结果：溴必利的生物利用度约为70%，多次给药后增加至约90%。从统计学角度来看，各剂型的生物利用度之间没有差异。
